How many drugs treat Atrial fibrillation?

Drug Landscape tracks 10 marketed treatments for Atrial fibrillation (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/atrial-fibrillation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Atrial fibrillation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atrial fibrillation (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Atrial fibrillation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Onoact	LANDIOLOL	Aop Hlth Us	landiolol	Beta-1 adrenergic receptor	2024-01-01
Multaq	DRONEDARONE	Sanofi	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily KQT member 2	2009-01-01
Tikosyn	DOFETILIDE	Pfizer	Antiarrhythmic [EPC]	Potassium voltage-gated channel subfamily H member 2	1999-01-01
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Zebeta	BISOPROLOL	Teva	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1992-01-01
Brevibloc In Plastic Container	ESMOLOL	Pfizer	beta-Adrenergic Blocker	Beta-1 adrenergic receptor	1986-01-01
Cardizem	diltiazem	Generic (originally Tanabe Seiyaku)	Calcium channel blocker (non-dihydropyridine, benzothiazepine)	Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1	1982-11-05
Acylanid	ACETYLDIGITOXIN	Novartis	acetyldigitoxin	Sodium/potassium-transporting ATPase	1975-01-01
Inderal	propranolol	Generic (originally ICI/AstraZeneca)	Non-selective beta-blocker	Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2	1967-11-13
Persantine	DIPYRIDAMOLE	Boehringer Ingelheim	Platelet Aggregation Inhibitor [EPC]	Equilibrative nucleoside transporter 1	1961-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Atrial fibrillation
Boehringer Ingelheim · 2 drugs in Atrial fibrillation
· 2 drugs in Atrial fibrillation
Bayer · 1 drug in Atrial fibrillation
Eli Lilly · 1 drug in Atrial fibrillation
Generic (originally Burroughs Wellcome/GSK) · 1 drug in Atrial fibrillation
Generic (originally ICI/AstraZeneca) · 1 drug in Atrial fibrillation
Generic (originally Sanofi/BMS) · 1 drug in Atrial fibrillation
Generic (originally Tanabe Seiyaku) · 1 drug in Atrial fibrillation
Novartis · 1 drug in Atrial fibrillation
Sanofi · 1 drug in Atrial fibrillation
Teva · 1 drug in Atrial fibrillation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Atrial fibrillation:

Cite this brief

Drug Landscape (2026). Atrial fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atrial-fibrillation. Accessed 2026-06-10.

Atrial fibrillation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing